Company intelligence / Profile preview
Ichnos Sciences Inc.
New York, New York, USAbioalps.org ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Phase 1
01
Overview
Ichnos Sciences has three clinical-stage oncology assets under investigation, with ISB 2001 (BCMA x CD38 x CD3 trispecific antibody) currently in Phase 1 trials for relapsed/refractory multiple myeloma. Two of their molecules have received orphan drug designation from the U.S. FDA.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- BiologicsMultispecific antibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Glenmark Pharmaceuticals Ltd.
Beyond the preview
Go deeper on Ichnos Sciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichnos Sciences Inc..